Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
366 active trials6 approved drugs33 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,281 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03482102 | Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer | active not recruiting | Phase 2 | 37 | Massachusetts General HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07030140 | Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma | recruiting | Phase 2 | 38 | Jinbo YueOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07099547 | Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract Carcinoma | recruiting | Phase 2 | 60 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07561775 | Adebrelimab Plus S-1 for Resected Cholangiocarcinoma | not yet recruiting | Phase 2 | 40 | Xingjun GuoOTHER | 0 | May 1, 2026 | clinicaltrials |
| NCT07478523 | FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers(FAPDIG) | recruiting | Phase 2 | 120 | University Hospital, BordeauxOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05655949 | Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio | recruiting | Phase 2 | 30 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT05967182 | A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06708663 | HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 124 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06431490 | A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer | recruiting | Phase 1 / Phase 2 | 102 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07514533 | The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma | not yet recruiting | Phase 2 | 60 | Sir Run Run Shaw HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT05733598 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | recruiting | Phase 2 | 60 | Replimune, Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07450976 | A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer | recruiting | Phase 2 | 151 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06178445 | Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer(TRAP-BTC) | active not recruiting | Phase 2 | 24 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05849480 | A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) | recruiting | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07392541 | Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer | recruiting | Phase 1 / Phase 2 | 29 | Tongji HospitalOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06859684 | Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)(HAIC-quad) | recruiting | Phase 2 | 25 | West China HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06938321 | A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer | recruiting | Phase 1 / Phase 2 | 135 | AkesoINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04969887 | Combination Immunotherapy in Rare Cancers Under InvesTigation(MOST-CIRCUIT) | active not recruiting | Phase 2 | 240 | Olivia Newton-John Cancer Research InstituteOTHER | 2 | Feb 27, 2026 | clinicaltrials |
| NCT06789848 | Ligufalimab and Cadonilimab in Advanced Liver Cancers | recruiting | Phase 2 | 64 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07437287 | Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers(CROCOBIL) | not yet recruiting | Phase 2 / Phase 3 | 160 | UNICANCEROTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07432568 | A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT04430738 | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | active not recruiting | Phase 2 | 40 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT06178588 | Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma | active not recruiting | Phase 2 | 15 | University of Kansas Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05451290 | Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer | active not recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05430698 | PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma | recruiting | Phase 2 | 62 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07223307 | REGULUS: MRI-guided Adaptive SABR for Liver Cancers | recruiting | Phase 2 | 62 | Stanford UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07398339 | Cosiporfin Sodium for Injection Photodynamic Therapy(DVDMS) | recruiting | Phase 2 | 30 | Shanghai Guangsheng Biopharmaceutical Co., LtdINDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07201519 | Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy | recruiting | Phase 2 | 80 | Michael J Cavnar, MDOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06313203 | HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT)(TOMCAT) | recruiting | Phase 2 | 39 | Oslo University HospitalOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04005339 | NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer | active not recruiting | Phase 2 | 48 | Georgetown UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT04781192 | The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers | active not recruiting | Phase 1 / Phase 2 | 40 | University of Kansas Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07364305 | HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC(Lalo) | recruiting | Phase 2 | 50 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07351591 | A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers | not yet recruiting | Phase 2 | 88 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jan 20, 2026 | clinicaltrials |
| NCT07353827 | FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05668884 | GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04353375 | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 / Phase 3 | 235 | HutchmedINDUSTRY | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07296666 | Adjuvant Chemotherapy for BTC Based on 3D-PTA | not yet recruiting | Phase 2 | 98 | Fudan UniversityOTHER | 0 | Dec 22, 2025 | clinicaltrials |
| NCT07291947 | PULSAR Combined With Immunotherapy and Chemotherapy | recruiting | Phase 1 / Phase 2 | 60 | Wang XinOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07282262 | An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy. | recruiting | Phase 2 | 300 | Peking Union Medical College HospitalOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT04238637 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | active not recruiting | Phase 2 | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05174650 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | active not recruiting | Phase 2 | 27 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07267078 | Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer | recruiting | Phase 2 | 45 | Peking Union Medical College HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06440993 | Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 42 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT07159217 | Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 65 | Peking Union Medical College HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
Data updated 22 days agoSource updated May 4, 2026source: clinicaltrials